Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
48 hedge funds and large institutions have $43.3M invested in Carisma Therapeutics in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 11 closing their positions.
31% more call options, than puts
Call options by funds: $467K | Put options by funds: $357K
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
2% more funds holding
Funds holding: 47 → 48 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.45% less ownership
Funds ownership: 2.42% → 1.97% (-0.45%)
46% less capital invested
Capital invested by funds: $80.2M → $43.3M (-$36.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$1.27M |
| 2 |
Millennium Management
New York
|
+$430K |
| 3 |
PVI
Pura Vida Investments
New York
|
+$319K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$286K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$275K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$14.6M |
| 2 |
NC
Nexthera Capital
New York
|
-$2.53M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.35M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$465K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$181K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
51
Virtu Financial
New York
| – | -$39K | -898 | Closed |
|
52
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$30K | -700 | Closed |
|
53
Renaissance Technologies
New York
| – | -$30K | -700 | Closed |
|
54
Squarepoint
New York
| – | -$29K | -672 | Closed |
|
55
Parallax Volatility Advisers
San Francisco,
California
| – | +$64 | +2 | New |
|
|
TRCT
56
Tower Research Capital (TRC)
New York
| – | +$415 | +13 | New |
|
57
Bank of America
Charlotte,
North Carolina
| – | +$542 | +17 | New |
|
CARM Hedge Fund Activity: Q4 2018 in Review
48 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2018, worth a combined $43.3M — down 46% from $80.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CARM positions and 11 closed out — a net gain of 1 holder — while 12 added to existing stakes and 10 trimmed.
The largest buyer was Kingdon Capital Management, adding an estimated $1.27M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $14.6M sold.
- 48 institutional investors held Carisma Therapeutics (CARM) as of Q4 2018, up from 47 in Q3 2018.
- Funds reported $43.3M of Carisma Therapeutics stock for Q4 2018, down 46% quarter-over-quarter.
- 12 funds opened new Carisma Therapeutics positions in Q4 2018 and 11 closed out, a net change of +1 holder.
- The largest Carisma Therapeutics buyer in Q4 2018 was Kingdon Capital Management, an estimated $1.27M added.
- The largest Carisma Therapeutics seller in Q4 2018 was Avoro Capital Advisors, an estimated $14.6M sold.
Based on aggregated 13F filings for Q4 2018.